ERBB2 and breast carcinoma: The COGNITION-GUIDE trial investigates a combination of treatments—including atezolizumab, inavolisib, ipatasertib, olaparib, sacituzumab govitecan, trastuzumab, and pertuzumab—for early-stage (I-III) high risk TNBC or HER2-positive breast cancer [69].